NCT05133635View on ClinicalTrials.gov

High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 1, 2021

Primary Completion Date

April 1, 2021

Study Completion Date

April 1, 2021

Conditions
COVID-19 Virus InfectionCytokine StormCorticosteroidTocilizumab
Interventions
DRUG

Methylprednisolone

Patients with the clinical and laboratory diagnosis of cytokine storm will receive methylprednisolone 250 mg for 3 days.

DRUG

Tocilizumab

Patients with the clinical and laboratory diagnosis of cytokine storm will receive tocilizumab 400-800 mg for one time.

Sponsors

Lead Sponsor

Marmara University
All Listed Sponsors
lead

Marmara University

OTHER

NCT05133635 - High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19 | Biotech Hunter | Biotech Hunter